全球香港腳市場按疾病類型、治療類型、給藥途徑、分銷管道和地區分類

2025 年全球香港腳市場規模估計為 14.1 億美元，預計到 2032 年將達到 19.9 億美元，2025 年至 2032 年的複合年成長率為 5.0%。

數字。 2025年全球市場佔有率香港腳市佔率（按地區）

香港腳，也稱為香港腳，是一種常見的真菌感染疾病，會影響足部皮膚，尤其是腳趾之間的皮膚，但也會擴散到腳趾甲和手部。這種真菌在溫暖、潮濕的環境中茁壯成長，例如運動員常見的汗濕鞋子內，因此得名香港腳。這種病症的特徵是腳趾之間和腳底有搔癢、刺痛和灼熱感。受影響區域的皮膚可能會變紅、脫皮、破裂或起水泡。雖然這是一種令人不快的疾病，但通常症狀較輕，可以用非處方抗真菌藥物治療。對於持續或嚴重的情況，可能需要更強的處方箋治療。香港腳是由皮癬菌（一種生長在皮膚死皮外層的真菌）引起的。這種真菌很容易透過直接接觸受污染的表面或間接接觸毛巾、鞋子或衣服來傳播。公共淋浴設備、游泳池和更衣室是病毒傳播的熱點，運動員和健身者尤其容易受到感染。足部衛生在預防香港腳中扮演重要角色。這包括保持雙腳清潔乾燥、穿透氣的鞋子、定期更換襪子，以及不要在可能存在真菌的公共場所赤腳行走。患有香港腳的人也應注意不要將感染傳播到身體的其他部位或其他人。早期發現和治療香港腳非常重要，以防止感染疾病變得難以控制並導致更嚴重的繼發性細菌感染。了解原因、預防和治療方法可以幫助您有效地控制這種情況並保持足部健康。

市場動態：

全球香港腳市場受到感染疾病上升的推動，這主要是由於老年人口的成長、肥胖率的上升以及水上運動參與度的增加。人們對未治療的足部真菌感染疾病的影響的健康意識的提高也推動了自我診斷和非處方藥物治療。然而，替代治療方案，例如使用非處方（OTC）外用藥膏和粉劑的家庭療法，可能會阻礙處方藥的產生收入潛力。

本研究的主要特點

• 本報告對全球香港腳市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率(CAGR)。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
• 全球香港腳市場的主要企業簡介是根據公司亮點、產品系列、關鍵亮點、財務業績和策略等參數列出的。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球香港腳市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
• 相關人員將透過用於分析全球香港腳市場的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
• 增強健康和衛生意識
• 個人護理和運動保健支出增加
• 治療方案的技術進步
• 主要亮點
• 監管情景
• 近期動態
• 產品發布/核准
• PEST分析
• 波特分析
• 合併、收購和合作

第4章 全球香港腳市場-冠狀病毒（COVID-19）大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 2020 年至 2032 年全球香港腳市場（依藥物類別）

• 抗真菌藥物
• 組合使用

6. 2020 年至 2032 年全球香港腳市場（依疾病分類）

• 手指之間
• 唯一
• 水泡

7. 2020 年至 2032 年按給藥途徑分類的全球香港腳市場

• 外用
• 口服

8. 2020 年至 2032 年全球香港腳市場（依分銷通路分類）

• 醫院藥房
• 零售藥局
• 網路藥局

9. 2020 年至 2032 年按地區分類的全球香港腳市場

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東
• 非洲

第10章 競爭格局

• 公司簡介
  • Perrigo Company Plc.
  • Novartis AG
  • Valeant Pharmaceuticals International
  • GlaxoSmithKline plc
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Glenmark Pharmaceutical Ltd
  • Taro Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals Inc
  • Aurobindo Pharma Ltd

第 11 章 章節

• 參考
• 調查方法
• 關於出版商

Global Athlete's foot Market is estimated to be valued at USD 1.41 Bn in 2025 and is expected to reach USD 1.99 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2032.

Figure. Global Athlete's foot Market Share (%), By Region 2025

Athlete's foot, also known as tinea pedis, is a common fungal infection that affects the skin on the feet, particularly the spaces between the toes, but can also spread to the toenails and hands. It is named athlete's foot because it is frequently seen in athletes, as the fungus thrives in warm, moist environments, such as the inside of sweaty shoes, which are common among sports participants. This condition is characterized by itching, stinging, and burning sensations between the toes or on the soles of the feet. The affected skin may also become red, flaky, cracked, or blistered. Although the condition can be uncomfortable, it is generally mild and can be treated with over-the-counter antifungal medications. In persistent or severe cases, prescription-strength treatments may be necessary. Athlete's foot is caused by dermatophytes, a type of fungus that grows on the dead outer layer of skin. The fungus spreads easily through direct contact with contaminated surfaces or through indirect contact with towels, shoes, or clothing. Communal showers, swimming pools, and locker rooms are hotspots for transmission, making athletes and gym-goers particularly susceptible. Good foot hygiene plays a crucial role in preventing athlete's foot. This includes keeping the feet clean and dry, wearing breathable footwear, changing socks regularly, and avoiding walking barefoot in public places where the fungus may be present. Individuals with athlete's foot should also be careful not to spread the infection to other parts of their body or to other people. Early detection and treatment of athlete's foot are important to prevent the infection from becoming more difficult to manage or leading to more serious secondary bacterial infections. Understanding the causes, prevention, and treatment options enables individuals to effectively deal with this condition and maintain good foot health.

Market Dynamics:

The global athlete's foot market is primarily driven by the rising prevalence of the infection due to a growing geriatric population, increasing obesity rates, and greater participation in aquatic activities. Growing health awareness regarding implications of untreated fungal infections of feet is also supporting self-diagnosis and over-the-counter medication. However, alternative treatment options such as home remedies using over-the-counter (OTC) topical creams and powders may hinder revenue generation potential for prescription drugs.

Key features of the study:

• This report provides in-depth analysis of the global athlete's foot market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global athlete's foot market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Perrigo Company Plc., Novartis AG, Valeant Pharmaceuticals International, GlaxoSmithKline plc, Bayer AG, Teva Pharmaceuticals Industries Ltd., Mylan NV, Glenmark Pharmaceutical Ltd, Taro Pharmaceutical Industries Ltd., Camber Pharmaceuticals Inc, Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global athlete's foot market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global athlete's foot market

Detailed Segmentation:

• Global Athlete's Foot Market, By Drug Class
  • Antifungals
  • Combination
• Global Athlete's Foot Market, By Disease Indication
  • Interdigital
  • Plantar
  • Vesicular
• Global Athlete's Foot Market, By Route of Administration
  • Topical
  • Oral
• Global Athlete's Foot Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Athlete's Foot Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Perrigo Company Plc.
  • Novartis AG
  • Valeant Pharmaceuticals International
  • GlaxoSmithKline plc
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Glenmark Pharmaceutical Ltd
  • Taro Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals Inc
  • Aurobindo Pharma Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Athlete's Foot, By Drug Class
  • Market Athlete's Foot, By Disease Indication
  • Market Athlete's Foot, By Route of Administration
  • Market Athlete's Foot, By Distribution Channel
  • Market Athlete's Foot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
• Growing health and hygiene awareness
• Increasing spending on personal care and sports healthcare
• Technological advancements in treatment options
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Athlete's Foot Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Athlete's Foot Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Antifungals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Combination
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Athlete's Foot Market, By Disease Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Interdigital
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Plantar
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vesicular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Athlete's Foot Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Athlete's Foot Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Athlete's Foot Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2020 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Company Profile
  • Perrigo Company Plc.
• Drug Class Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Novartis AG
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Valeant Pharmaceuticals International
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • GlaxoSmithKline plc
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bayer AG
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Teva Pharmaceuticals Industries Ltd.
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Mylan NV
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Glenmark Pharmaceutical Ltd
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Taro Pharmaceutical Industries Ltd.
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Camber Pharmaceuticals Inc
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Aurobindo Pharma Ltd
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About us